How did a gut hormone that disappeared in seconds become one of the biggest drug classes in the world?

In this episode, I walk through the story of GLP-1, from early scientific discovery and the Gila monster breakthrough to Novo Nordisk’s drug design strategy, Eli Lilly’s competitive push, and the shift that turned GLP-1 from a diabetes treatment into something much bigger.

This is a story about how a hard biological problem became a pharmaceutical platform, and how that platform began to change the way medicine thinks about obesity, metabolism, and chronic disease.

Timestamps

• 00:08 Intro: The 90-Second Hormone
• 02:23 The Gut’s Hidden Signal
• 05:01 The Discovery of GLP-1
• 10:32 The Gila Monster Breakthrough
• 16:04 Novo Solves the Delivery Problem
• 19:43 How GLP-1 Became a Platform
• 25:46 Beyond Diabetes
• 30:28 Lilly Raises the Benchmark
• 32:43 The Broader Implications of GLP-1
• 43:22 The future of GLP-1
• 49:14 When the Science Meets the System

What does it actually take to turn a scientific breakthrough into a drug patients can access?

In this episode, I look at the manufacturer side of the healthcare system, the part that absorbs scientific failure, funds long-shot bets, and then enters a second battle after the science succeeds. Because FDA approval is not the finish line. It is the point where a therapy enters the real commercial system: one shaped by patent clocks, launch pricing, payer resistance, formulary access, rebates, and budget pressure.

This is a story about the economics of failure, the logic of blockbuster drugs, and the central tension at the heart of modern pharma: scientifically essential, politically unpopular, financially powerful, and commercially constrained at the same time.

Between the lab bench and the patient sits a market that does not simply reward innovation. It prices it, filters it, delays it, and redistributes its value.

Timestamps

• 00:00 Intro: The Drug Exists. Access Still Breaks Down
• 05:44 FDA Approval Is Not the Finish Line
• 09:41 Inside the R&D Risk Machine
• 13:24 Why Most Drug Trials Fail
• 15:32 The Patent Clock Starts Early
• 24:39 Why U.S. Drug Prices Run Higher
• 29:19 The Gross-to-Net Bubble
• 40:16 The Pharma Paradox
• 44:05 The IRA Changes the Game
• 50:59 Invention Is Not Enough

If your doctor writes a prescription, who actually decides whether you get it, where you fill it, and what you pay?

In this episode, I unpack the hidden role of pharmacy benefit managers, or PBMs, the intermediaries that sit between drugmakers, insurers, employers, pharmacies, and patients. PBMs do not invent drugs or prescribe them, but they often control formularies, prior authorization, specialty pharmacy channels, and the financial terms that shape access.

I trace how PBMs evolved from claims processors into powerful gatekeepers, explain how rebates, spread pricing, specialty pharmacy, and step therapy work, and examine the central debate: are PBMs lowering costs, or making the system more opaque while controlling who gets what medicine?

From insulin and biosimilars to specialty drug markups and the latest reform pressure, this is a story about the financial architecture between the prescription pad and the patient.

Timestamps

• 00:00 — Cold open
• 03:23 — The pharmacy counter mystery
• 12:28 — Meet the PBM
• 16:35 — The evolution of PBMs
• 22:25 — How the machine works
• 38:01 — Why PBMs grew so powerful
• 49:33 — Critics vs. Defense
• 57:01 — What this means